WA
CORT icon

Waverly Advisors’s Corcept Therapeutics CORT Stock Holding History

Waverly Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$306K Buy
+3,516
New +$212K ﹤0.01% 1405

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Waverly Advisors's CORT Position: Q2 2026 in Review

Waverly Advisors opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 3,516 shares worth $306K. The stake represents ﹤0.01% of the portfolio and ranks #1405 among its holdings.

422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Waverly Advisors held 3,516 shares of Corcept Therapeutics worth $306K as of Q2 2026.
  • Corcept Therapeutics was a new Waverly Advisors position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Waverly Advisors's portfolio in Q2 2026, its #1405 holding.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Waverly Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.